Severely Impaired von Willebrand Factor-Dependent Platelet Aggregation in Patients With a Continuous-Flow Left Ventricular Assist Device (HeartMate II)
| Autor: | Finn Gustafsson, Kåre Sander, S. A. Mortensen, Jolanta Klovaite, Lars Bo Nielsen |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Blood Platelets Male medicine.medical_specialty Platelet Aggregation medicine.medical_treatment Hemorrhage Ventricular Function Left law.invention Ventricular Dysfunction Left Young Adult Von Willebrand factor law hemic and lymphatic diseases Internal medicine Artificial heart von Willebrand Factor medicine Humans Platelet heart-assist device International Normalized Ratio Heart Failure biology business.industry Impaired platelet aggregation Stroke Volume Middle Aged medicine.disease Anti-Bacterial Agents Ristocetin Coagulation Ventricular assist device Heart failure platelets Circulatory system Cardiology biology.protein Female Heart-Assist Devices business Cardiology and Cardiovascular Medicine Platelet Aggregation Inhibitors |
| Zdroj: | Journal of the American College of Cardiology. 53(23):2162-2167 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/j.jacc.2009.02.048 |
| Popis: | Objectives This study investigated the influence of the mechanical blood pump HeartMate II (HMII) (Thoratec Corporation, Pleasanton, California) on blood coagulation and platelet function. Background HMII is an implantable left ventricular assist device used for the treatment of heart failure. Patients treated with HMII have increased bleeding tendencies. Methods We measured agonist-induced platelet aggregation in 16 patients on HMII support. Results The von Willebrand factor (vWF)-dependent ristocetin-induced platelet aggregation was impaired in 11 of the 16 patients, of which 12 had experienced at least 1 minor or major bleeding episode. The impaired ristocetin-induced platelet aggregation was associated both with decreased specific activity of plasma vWF, presumably due to lack of high molecular weight vWF multimers, as well as with attenuated function of the platelets themselves. Conclusions The results imply that HMII treatment is associated with impaired platelet aggregation, which may contribute to an increased tendency to bleed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|